These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2405486)

  • 1. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
    McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
    Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
    Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
    Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
    Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
    [No Abstract]   [Full Text] [Related]  

  • 4. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.
    Ross EK; Fuerst TR; Orenstein JM; O'Neill T; Martin MA; Venkatesan S
    AIDS Res Hum Retroviruses; 1991 May; 7(5):475-83. PubMed ID: 1873082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
    Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
    Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.
    Erickson-Viitanen S; Manfredi J; Viitanen P; Tribe DE; Tritch R; Hutchison CA; Loeb DD; Swanstrom R
    AIDS Res Hum Retroviruses; 1989 Dec; 5(6):577-91. PubMed ID: 2692658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of peptide-based HIV proteinase inhibitors.
    Roberts NA; Martin JA; Kinchington D; Broadhurst AV; Craig JC; Duncan IB; Galpin SA; Handa BK; Kay J; Kröhn A
    Science; 1990 Apr; 248(4953):358-61. PubMed ID: 2183354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
    Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
    Serio D; Singh SP; Cartas MA; Weber IT; Harrison RW; Louis JM; Srinivasan A
    Protein Eng; 2000 Jun; 13(6):431-6. PubMed ID: 10877854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles.
    Park J; Morrow CD
    J Virol; 1992 Nov; 66(11):6304-13. PubMed ID: 1383561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
    Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
    Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.
    Wagner R; Fliessbach H; Wanner G; Motz M; Niedrig M; Deby G; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):117-37. PubMed ID: 1456888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interaction of gag polyprotein-precursors p55 and p48 with p160gag-pol during formation of virus-like particles of HIV-1 with recombinant strains of vaccinia virus].
    Iordanskiĭ SN; Lideman LF; Chikova AK; Gibadulin RA
    Vopr Virusol; 1997; 42(5):205-8. PubMed ID: 9424843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
    Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
    J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
    Park J; Morrow CD
    Virology; 1993 Jun; 194(2):843-50. PubMed ID: 8503189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
    el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
    J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro inhibition of HIV-1 proteinase by cerulenin.
    Moelling K; Schulze T; Knoop MT; Kay J; Jupp R; Nicolaou G; Pearl LH
    FEBS Lett; 1990 Feb; 261(2):373-7. PubMed ID: 1690152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.